Cancer Progress Report - Cancer Progress Report 2014

26. Centers for Disease Control and Prevention. Vital signs: walking among adults—United States, 2005 and 2010.

MMWR Morb Mortal Wkly Rep 2012;61:595–601.

27. Calle EE, Rodriguez C, Walker-;urmond K, ;un MJ.

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–38.

28. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, Mc Tiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:815–40.

29. Cao Y, Ma J. Body mass index, prostate cancer-speci;c mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila)

2011;4:486–501.

30. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, et al. A review of human carcinogens—part D: radiation. Lancet Oncol 2009;10:751–2.

31. Koh HK, Geller AC, Miller DR, Grossbart TA, Lew RA.

Prevention and early detection strategies for melanoma and skin cancer. Current status. Arch Dermatol 1996;132:436–43.

32. Parkin DM, Mesher D, Sasieni P. 13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer 2011; 105(Suppl 2):S66-9.

33. Wehner MR, Chren MM, Nameth D, Choudhry A, Gaskins M, Nead KT, et al. International Prevalence of indoor tanning: a systematic review and meta-analysis. JAMA Dermatol 2014;150:390–400.

34. Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012;345:e4757.

35. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006;15:2546–8.

36. Green AC, Williams GM, Logan V, Strutton GM.

Reduced melanoma a;er regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29:257– 63.

37. Centers for Disease Control and Prevention. Sunburn and sun protective behaviors among adults aged 18- 29 years—United States, 2000–2010. MMWR Morb Mortal Wkly Rep 2012;61:317–22.

38. Centers for Disease Control and Prevention. Use of indoor tanning devices by adults—United States, 2010.

MMWR Morb Mortal Wkly Rep 2012;61:323–6.

39. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al. Youth risk behavior surveillance— United States, 2011. MMWR Surveill Summ 2012;61: 1– 162.

40. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part B: biological agents. Lancet Oncol 2009;10:321–2.

41. Chang Y, Moore PS. Merkel cell carcinoma: a virus-
induced human cancer. Annu Rev Pathol 2012;7:123–44.
42. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F,
Forman D, et al. Global burden of cancers attributable
to infections in 2008: a review and synthetic analysis.
Lancet Oncol 2012;13:607–15.

43. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. ;e increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271–8.

44. Accelerating HPV vaccine uptake: urgency for action to prevent cancer. A report to the President of the United States from the President’s Cancer Panel. Bethesda (MD): National Cancer Institute; 2014.

45. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.

46. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011;154:319–28.

47. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293–300.

48. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43: 66–72.

49. Centers for Disease Control and Prevention. Human papillomavirus-associated cancers—United States, 2004–2008. MMWR Morb Mortal Wkly Rep 2012;61:258–61.

50. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, et al. AACR Cancer progress report 2012. Clin Cancer Res 2012;18:S1–100.

51. Yang JC, Lu CW, Lin CJ. Treatment of infection: current status and future concepts. World J Gastroenterol 2014;20:5283–93.

52. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348–55.

53. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521–31.

54. LeFevre ML. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161: 58–66 55. Liang TJ, Ghany MG. ;erapy of hepatitis C–back to the future. N Engl J Med 2014;370:2043–7.